With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic

Just a month after approving the first cancer therapy that uses genetically engineered immune cells collected from patients, the Food and Drug Administration (FDA) has now cleared a second such therapy.

The approval, announced October 18, covers the use of axicabtagene ciloleucel (Yescarta™) for patients with large-B-cell lymphomas whose cancer has progressed after receiving at least two prior treatment regimens. Large B-cell lymphomas include diffuse large B-cell lymphoma (DLBCL), the most common type; primary mediastinal large B-cell lymphoma; high-grade B-cell lymphoma; and transformed follicular lymphoma.